{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:17:34Z","timestamp":1790864254240,"version":"4.1.0"},"reference-count":14,"publisher":"S. Karger AG","issue":"2-3","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2005]]},"abstract":"<i>Background:<\/i><i>Pseudomonas aeruginosa<\/i> can rapidly acquire resistance to antibiotics, including fluoroquinolones and carbapenems. <i>Methods:<\/i> We characterized fluoroquinolone, carbapenem and other \u03b2-lactam susceptibilities and analyzed fluoroquinolone and carbapenem resistance in 16 clinical isolates of levofloxacin-resistant <i>P. aeruginosa<\/i>. <i>Results:<\/i> All levofloxacin-resistant isolates showed high MICs (\u226732 \u00b5g\/ml) for fluoroquinolones including norfloxacin, levofloxacin, sparfloxacin, gatifloxacin and pazufloxacin, whereas the MICs for sitafloxacin were between 2 and 16 \u00b5g\/ml. These isolates had both a Thr83Ile mutation in GyrA and a Ser87Leu mutation in ParC. An additional mutation, Glu469Asp in GyrB, was detected in 3 isolates. Three of 16 isolates found during antibiotic therapy showed resistance to carbapenems (MIC, 16\u201332 \u00b5g\/ml) because of a reduced production of OprD. Fluoroquinolones, \u03b2-lactams and sulfamethoxazole-trimethoprim were used for 3 months before the isolation of levofloxacin-resistant <i>P.<\/i><i>aeruginosa<\/i>. <i>Conclusions:<\/i> Emergence of resistant isolates to both fluoroquinolones and carbapenems during antibiotic therapy is a serious clinical problem. Our results suggest that susceptibilities to fluoroquinolones as well as carbapenems should be monitored during a prolonged course of antibiotic therapy against <i>P. aeruginosa<\/i> infection.<\/jats:p>","DOI":"10.1159\/000085612","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T08:47:15Z","timestamp":1115196435000},"page":"70-75","source":"Crossref","is-referenced-by-count":10,"title":["Characterization of Fluoroquinolone and Carbapenem Susceptibilities in Clinical Isolates of Levofloxacin-Resistant <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1159","volume":"51","author":[{"given":"Hideaki","family":"Muramatsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakuni","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2005,6,3]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159%2F000048550"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159%2F000063867"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159%2F000074529"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1086%2F514909"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F48.4.553"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128%2FAAC.45.8.2263-2268.2001"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1089%2Fmdr.1998.4.257"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1086%2F338782"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0378-1097%2800%2900090-2"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2F0378-1119%2894%2990529-0"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1089%2F107662903765826831"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093%2Fjac%2F47.3.247"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1086%2F324346"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1086%2F338237"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/85612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/85612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:53:22Z","timestamp":1745466802000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000085612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":14,"journal-issue":{"issue":"2-3","published-online":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000085612","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005]]}}}